ATE512966T1 - Pyrazolo-pyrimidin-derivate als mglur2- antagonisten - Google Patents

Pyrazolo-pyrimidin-derivate als mglur2- antagonisten

Info

Publication number
ATE512966T1
ATE512966T1 AT06706609T AT06706609T ATE512966T1 AT E512966 T1 ATE512966 T1 AT E512966T1 AT 06706609 T AT06706609 T AT 06706609T AT 06706609 T AT06706609 T AT 06706609T AT E512966 T1 ATE512966 T1 AT E512966T1
Authority
AT
Austria
Prior art keywords
pyrazolo
pyrimidine derivatives
mglur2 antagonists
mglur2
antagonists
Prior art date
Application number
AT06706609T
Other languages
English (en)
Inventor
Mcarthur Silvia Gatti
Erwin Goetschi
Juergen Wichmann
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE512966T1 publication Critical patent/ATE512966T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06706609T 2005-02-11 2006-02-03 Pyrazolo-pyrimidin-derivate als mglur2- antagonisten ATE512966T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101027 2005-02-11
PCT/EP2006/000940 WO2006084634A1 (en) 2005-02-11 2006-02-03 Pyrazolo-pyrimidine derivatives as mglur2 antagonists

Publications (1)

Publication Number Publication Date
ATE512966T1 true ATE512966T1 (de) 2011-07-15

Family

ID=36090752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06706609T ATE512966T1 (de) 2005-02-11 2006-02-03 Pyrazolo-pyrimidin-derivate als mglur2- antagonisten

Country Status (18)

Country Link
US (1) US7361659B2 (de)
EP (1) EP1851225B1 (de)
JP (1) JP4708438B2 (de)
KR (1) KR100968291B1 (de)
CN (1) CN101115755B (de)
AR (1) AR052568A1 (de)
AT (1) ATE512966T1 (de)
AU (1) AU2006212457B2 (de)
BR (1) BRPI0607927A2 (de)
CA (1) CA2597608C (de)
ES (1) ES2365406T3 (de)
IL (1) IL184712A (de)
MX (1) MX2007009106A (de)
NO (1) NO20073876L (de)
RU (1) RU2402553C2 (de)
TW (1) TW200716120A (de)
WO (1) WO2006084634A1 (de)
ZA (1) ZA200706353B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085398A1 (de) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
US8207181B2 (en) 2008-03-06 2012-06-26 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
JP5309162B2 (ja) * 2008-03-06 2013-10-09 サノフイ 置換されたジヒドロ、トリヒドロ及びテトラヒドロシクロアルキルオキサゾロピリミジノン、その製造及び使用
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
RU2014120166A (ru) * 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
EP2666775A1 (de) 2012-05-21 2013-11-27 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
EP2925292A1 (de) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3-antagonisten zur behandlung von autistischen störungen
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (de) 2014-09-26 2016-03-30 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
HRP20240644T1 (hr) 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
JP6861154B2 (ja) 2014-12-03 2021-04-21 ヤンセン ファーマシューティカ エヌ.ベー. 放射標識されたmGluR2 PETリガンド
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
LT3389727T (lt) 2015-12-18 2020-10-12 Janssen Pharmaceutica Nv Radioaktyviai pažymėti mglur2/3 pet ligandai
EA037941B1 (ru) 2015-12-18 2021-06-09 Янссен Фармацевтика Нв ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
EP3440081A4 (de) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl-carboxamid-verbindungen und deren verwendung in der behandlung von medizinischen störungen
US11192892B2 (en) * 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201809693SA (en) 2016-05-05 2018-11-29 Lysosomal Therapeutics Inc SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3452455A4 (de) 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. Substituierte imdazo[1,2-]pyridine, substituierte imidazo[1,2-]pyrazine, verwandte verbindungen und deren verwendung bei der behandlung von erkrankungen
US10647710B2 (en) * 2017-01-09 2020-05-12 Medshine Discovery Inc. Thiazole derivative and applications thereof
KR102688238B1 (ko) 2017-11-24 2024-07-25 스미토모 파마 가부시키가이샤 6, 7-디히드로 피라졸로[1, 5-a]피라지논 유도체 및 그 의약 용도
JP7150368B2 (ja) * 2018-07-06 2022-10-11 フェーノ・セラピューティクス・カンパニー・リミテッド チアゾール系化合物の結晶形およびその応用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3356291B2 (ja) 1996-02-07 2002-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Crfレセプター拮抗薬としてのピラゾロピリミジン類
EP0891978B1 (de) 1997-07-18 2002-03-20 F. Hoffmann-La Roche Ag 5h-Thiazolo[3,2-a]pyrimidinderivate
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
SK13682003A3 (sk) * 2001-04-12 2004-07-07 F. Hoffmann-La Roche Ag Dihydrobenzo[b][1,4]diazepin-2-ónové deriváty ako mGluR2 antagonisty II
JP2006523707A (ja) * 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
HRP20080070T3 (en) * 2004-06-21 2008-05-31 F. Hoffmann - La Roche Ag Pyrrazolo-pyrimidine derivatives

Also Published As

Publication number Publication date
JP4708438B2 (ja) 2011-06-22
KR100968291B1 (ko) 2010-07-07
AU2006212457A1 (en) 2006-08-17
US20060183756A1 (en) 2006-08-17
RU2402553C2 (ru) 2010-10-27
WO2006084634A1 (en) 2006-08-17
EP1851225A1 (de) 2007-11-07
JP2008530042A (ja) 2008-08-07
EP1851225B1 (de) 2011-06-15
CN101115755B (zh) 2013-01-16
MX2007009106A (es) 2007-09-11
US7361659B2 (en) 2008-04-22
RU2007128624A (ru) 2009-03-20
IL184712A0 (en) 2007-12-03
KR20070104592A (ko) 2007-10-26
CA2597608A1 (en) 2006-08-17
NO20073876L (no) 2007-09-10
AR052568A1 (es) 2007-03-21
IL184712A (en) 2013-05-30
CN101115755A (zh) 2008-01-30
ZA200706353B (en) 2009-09-30
BRPI0607927A2 (pt) 2009-10-20
TW200716120A (en) 2007-05-01
ES2365406T3 (es) 2011-10-04
CA2597608C (en) 2013-12-24
AU2006212457B2 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
ATE512966T1 (de) Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE531705T1 (de) Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
LT2495016T (lt) Bicikliniai heteroarilų junginiai
DK2194043T3 (da) Fremgangsmåder
ITMI20050728A1 (it) Formulazione innovativa
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ATE479676T1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
ATE533744T1 (de) N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten
DK1937650T3 (da) Heterocykliske forbindelser
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DE112005003586A5 (de) Bohrfutter
DK1957492T3 (da) Substituerede bicykliske pyrimidonderivater
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
EP1907393A4 (de) Introvertierte cucurbituril-verbindungen
DE602006003666D1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
DE502006002822D1 (de) Ges
FR2884161B1 (fr) Architecture de machine-outil
NO20055676D0 (no) X-Rail

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1851225

Country of ref document: EP